The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.

Daisuke Shishikura,Yu Kataoka,Satoshi Honda,Kohei Takata,Susan W Kim,Jordan Andrews,Peter J Psaltis,Michael Sweeney,Ewelina Kulikowski,Jan Johansson,Norman C W Wong,Stephen J Nicholls

American journal of cardiovascular drugs : drugs, devices, and other interventions（2019）

引用 32|浏览10

暂无评分

摘要

Apabetalone favorably modulated ultrasonic measures of plaque vulnerability in the population studied, which may relate to an increase in HDL particle concentrations. The clinical implications are currently being investigated in the phase 3 major adverse cardiac event outcomes trial BETonMACE.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要